Diseases [C] » Eye Diseases [C11] » Retinal Diseases » Retinal Degeneration » Macular Degeneration
Description
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms. MeSH
Hierarchy View
Subtype Terms (5)
Geographic Atrophy
44 drugs (11 approved, 33 experimental)
Macular Edema
153 drugs (74 approved, 79 experimental)
Stargardt Disease
14 drugs (4 approved, 10 experimental)
Vitelliform Macular Dystrophy
1 approved drug
Wet Macular Degeneration
62 drugs (26 approved, 36 experimental)
Approved Indicated Drugs (7)
Phase 4 Indicated Drugs (14)
Phase 3 Indicated Drugs (27)
Phase 1 Indicated Drugs (41)
Other Experimental Indicated Drugs (33)
Organization Involved with Phase 4 Indications (71)
Augenabteilung Allgemeines Krankenhaus Linz
Greater Houston Retina Research
Huazhong University of Science and Technology
Institut de la Macula y la Retina
Retinal Consultants of Arizona
Retina Research Institute, LLC
Retina Vitreous Associates of Florida
The New York Eye & Ear Infirmary
Universidad Complutense de Madrid
Organization Involved with Phase 3 Indications (77)
Asociación para Evitar la Ceguera en México
Centre Hospitalier Intercommunal Creteil
Chengdu Kanghong Biotech Co.,Ltd.
Chinese Academy of Medical Sciences
Icahn School of Medicine at Mount Sinai
Laboratorio Elea S.A.C.I.F. y A.
Mid-Atlantic Retina Consultations, Inc.
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Office of Dietary Supplements (ODS)
Oregon Health and Science University
Rocky Mountain Retina Consultants
Organization Involved with Phase 2 Indications (124)
Assistance Publique - Hôpitaux de Paris
Catholic University of Sacred Heart, Rome
Hamilton Health Sciences Corporation
Hôpital ophtalmique Jules-Gonin (HOJG)
J. Arch McNamara Research Fund
LuEsther T. Mertz Retinal Research Center
Manhattan Eye, Ear & Throat Hospital
Murray Ocular Oncology & Retina
Northern California Retina Vitreous Associates
Ophthalmic Consultants of Boston
People's Liberation Army of China
Regenerative Patch Technologies
Retina Associates of Western New York
Retina Diagnostic & Treatment Associates, LLC
Retinal Consultants Medical Group
Snyder, Robert W., M.D., Ph.D., P.C.
Southeast Clinical Research Associates, LLC
Southern California Desert Retina Consultants, MC
Stargazer Pharmaceuticals, Inc.
The Digital Angiography Reading Center (DARC)
Universidad Autonoma de Barcelona
University of California, Davis
University of Illinois at Chicago
Organization Involved with Phase 1 Indications (38)
Organization Involved with Other Experimental Indications (47)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
